Page 2,147«..1020..2,1462,1472,1482,149..2,1602,170..»

Researchers at UVa. Create Fish Embryo from Stem Cells

Posted: April 5, 2014 at 6:00 am

April 4, 2014

The University of Virginia School of Medicine has made a major scientific breakthrough. Scientists working in the Department of Cell Biology have been able to create a fish embryo using stem cells.

The breakthrough comes after years of research into how embryonic stem cells work. Scientists were able to determine that it only takes two signals to start the process of development that lead to the fish embryo.

This discovery is also a major step toward being able to grow entire organs using stem cells.

"Of course now, of we know how to instruct the cells and make heart cells," says Dr. Chris Thisse. "The hope - not for tomorrow, of course- but the hope is just, you can, you know, make a new heart."

The new embryo, while slightly smaller than a normal fish embryo, has everything that an average fish would have at this stage in development.

Scientists say the next step is to test the stem cells of mice to see if they can trigger the development of a mouse embryo.

If the results can be reproduced, scientists are certain they could complete successful tests on human stem cells as well.

Read the original:
Researchers at UVa. Create Fish Embryo from Stem Cells

Posted in Stem Cells | Comments Off on Researchers at UVa. Create Fish Embryo from Stem Cells

Scientists smash barrier to growing organs from stem cells

Posted: April 5, 2014 at 6:00 am

20 hours ago by Josh Barney U.Va. scientists Bernard and Chris Thisse have created a zebrafish embryo by instructing stem cells.

(Phys.org) Scientists at the University of Virginia School of Medicine have overcome one of the greatest challenges in biology and taken a major step toward being able to grow whole organs and tissues from stem cells. By manipulating the appropriate signaling, the U.Va. researchers have turned embryonic stem cells into a fish embryo, essentially controlling embryonic development.

The research will have dramatic impact on the future use of stem cells to better the human condition, providing a framework for future studies in the field of regenerative medicine aimed at constructing tissues and organs from populations of cultured pluripotent cells.

In accomplishing this, U.Va. scientists Bernard and Chris Thisse have overcome the most massive of biological barriers. "We have generated an animal by just instructing embryonic cells the right way," said Chris Thisse of the School of Medicine's Department of Cell Biology.

The importance of that is profound. "If we know how to instruct embryonic cells," she said, "we can pretty much do what we want." For example, scientists will be able one day to instruct stem cells to grow into organs needed for transplant.

Directing Embryonic Development

The researchers were able to identify the signals sufficient for starting the cascade of molecular and cellular processes that lead to a fully developed fish embryo. With this study came an answer to the longstanding question of how few signals can initiate the processes of development: amazingly, only two.

The study has shed light on the important roles these two signals play for the formation of organs and full development of a zebrafish embryo. Moreover, the Thisses are now able to direct embryonic development and formation of tissues and organs by controlling signal locations and concentrations.

The embryo they generated was smaller than a normal embryo, because they instructed a small pool of embryonic stem cells, but "otherwise he has everything" in terms of appropriate development, said Bernard Thisse of the Department of Cell Biology.

Their next steps will be to attempt to reproduce their findings using mice. They expect molecular and cellular mechanisms will be extremely similar in mice and other mammals including humans.

View original post here:
Scientists smash barrier to growing organs from stem cells

Posted in Stem Cells | Comments Off on Scientists smash barrier to growing organs from stem cells

UVA Breaks Barrier to Growing Organs From Stem Cells

Posted: April 5, 2014 at 6:00 am

Scientists at the University of Virginia have broken a major biological barrier by turning stem cells into a fully developed fish embryo. The research could be revolutionary for the field of regenerative medicine.

A husband and wife team at UVA's School of Medicine is heading up work centered on controlling cell development. By focusing on just two factors, they can direct the growth of organs and tissues.

Bernard and Christine Thisse have discovered that only two signals are needed to create a zebra-fish embryo out of stem cells. By instructing the embryonic cells in a specific way, they were able to produce Petri dishes of animals with a beating heart and functional nervous system. The researchers say this could be a major step in making human organs needed for transplants.

It gives lots of hope for regenerative medicine because if you are sick and you have a bad heart, and you're waiting for a transplant and you don't have a donor for you - you wait and maybe you will die. But if we can build a heart from your own cell, then I think you're on a good way, Christine Thisse stated.

The couple can also direct development by controlling signal locations and concentrations. The zebra-fish embryos are almost at full size within just about 24 hours.

The next step for the scientists is to reproduce their results in mice. They say they are confident the study will be successful now that they have the basic rules.

Scientists at the University of Virginia School of Medicine have overcome one of the greatest challenges in biology and taken a major step toward being able to grow whole organs and tissues from stem cells. By manipulating the appropriate signaling, the UVA researchers have turned embryonic stem cells into a fish embryo, essentially controlling embryonic development.

The research will have dramatic impact on the future use of stem cells to better the human condition, providing a framework for future studies in the field of regenerative medicine aimed at constructing tissues and organs from populations of cultured pluripotent cells.

In accomplishing this, UVA scientists Bernard and Chris Thisse have overcome the most massive of biological barriers. We have generated an animal by just instructing embryonic cells the right way, said Chris Thisse, PhD, of the School of Medicines Department of Cell Biology.

The importance of that is profound. If we know how to instruct embryonic cells, she said, we can pretty much do what we want. For example, scientists will be able one day to instruct stem cells to grow into organs needed for transplant.

Original post:
UVA Breaks Barrier to Growing Organs From Stem Cells

Posted in Stem Cells | Comments Off on UVA Breaks Barrier to Growing Organs From Stem Cells

FDA Approves CardioCell's Phase 2A Trial For CHF Stem Cell Therapy

Posted: April 5, 2014 at 5:53 am

By Estel Grace Masangkay

CardioCell LLC announced that it has received FDA approval for its investigational new drug (IND) application for a U.S.-based Phase IIA clinical study evaluating its allogeneic stem-cell therapy for patients with chronic heart failure (CHF).

Dr. Sergey Sikora, CardioCells president and CEO, said, With the FDAs IND approval, CardioCell is pleased to proceed with a Phase 2a CHF clinical trial based on the safety data reported in previous clinical trials using our unique, hypoxically grown stem cells. At the studys conclusion we will understand if our therapy produces signs of improvement in a population of patients with dilated CHF, a condition largely unaddressed by current therapies. Dilated CHF is characterized by a viable but non-functioning myocardium in which cardiomyocytes are alive but are not contracting as they should. We hope that unique properties of our itMSCs will transition patients cardiomyocytes from viable to functioning, eventually improving or restoring heart function.

The company has developed an ischemic tolerant mesenchymal stem cells (itMSC) treatment for the type of dilated CHF that is not related to coronary artery disease. The treatment could potentially apply to about 35 percent of CHF patients. Only CardioCells CHF therapies feature itMSCs, exclusively licensed from CardioCells parent company Stemedica Cell Technologies Inc. The company said Stemedicas bone marrow-derived, allogeneic MSCs are different from other MSCs because they are grown under hypoxic conditions that closely resemble the environment in which they thrive on in the body.

Dr. Stephen Epstein, CardioCells Scientific Advisory Board Chair, said Although past trials have tested the efficacy of different stem cells in patients with DCM, CardioCells itMSCs, grown under chronic hypoxic conditions, are unique. As compared to stem cells grown under normoxic conditions, they express higher levels of factors that could exert beneficial effects on the mechanisms contributing to myocardial dysfunction and disease progression. This study, therefore, provides an exciting opportunity to test the potential of these itMSCs to attenuate or eliminate these mechanisms and, in so doing, improve patient outcomes.

The trial entitled A Phase 2a, Single-Blind, Placebo-Controlled, Crossover, Multi-Center, Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-Tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Heart Failure of Non-Ischemic Etiology, will be conducted at Emory University, Northwestern University, and the University of Pennsylvania in May this year.

Visit link:
FDA Approves CardioCell's Phase 2A Trial For CHF Stem Cell Therapy

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on FDA Approves CardioCell's Phase 2A Trial For CHF Stem Cell Therapy

Stem Cells Muscle Fibers Breakthrough! – Video

Posted: April 4, 2014 at 11:40 pm


Stem Cells Muscle Fibers Breakthrough!
Amazing development with regard to creating and repairing muscle tissue from stem cells. My commentary on: Scientists develop #39;self-healing #39; muscles http://r...

By: mfromcanada1

More here:
Stem Cells Muscle Fibers Breakthrough! - Video

Posted in Stem Cell Videos | Comments Off on Stem Cells Muscle Fibers Breakthrough! – Video

Plant stem cells, non-ageing cells – Video

Posted: April 4, 2014 at 11:40 pm


Plant stem cells, non-ageing cells
The world #39;s leading science and technology ,Plant stem cells, non-ageing cells could use for food , health product,skincare products .

By: Cindy Ou-Rihgt

Go here to see the original:
Plant stem cells, non-ageing cells - Video

Posted in Stem Cell Videos | Comments Off on Plant stem cells, non-ageing cells – Video

Introduction to Stem Cell Therapy – Video

Posted: April 4, 2014 at 7:40 am


Introduction to Stem Cell Therapy
Dr. Michael Belich of Integrative Medical Clinics talks about Stem Cell Therapy basics. For more detailed information go to http://www.integrativemc.com.au.

By: Integrative Medical Clinics

Original post:
Introduction to Stem Cell Therapy - Video

Posted in Stem Cell Therapy | Comments Off on Introduction to Stem Cell Therapy – Video

Desiccated L4/5 disc five months after stem cell therapy by Dr Harry Adelson – Video

Posted: April 4, 2014 at 7:40 am


Desiccated L4/5 disc five months after stem cell therapy by Dr Harry Adelson
A decorated war hero, Chris, discusses the stem cell injection into his L4/5 disc by Dr Harry Adelson http://www.docereclinics.com.

By: Harry Adelson, N.D.

See more here:
Desiccated L4/5 disc five months after stem cell therapy by Dr Harry Adelson - Video

Posted in Stem Cell Therapy | Comments Off on Desiccated L4/5 disc five months after stem cell therapy by Dr Harry Adelson – Video

Umbilical Cord Stem Cell Therapy Clinical Trial for Multiple Sclerosis Gets Green Light

Posted: April 4, 2014 at 7:40 am

Dallas, TX (PRWEB) April 03, 2014

Translational Biosciences, a subsidiary of Medistem Panama, has received the green light for a phase I/II clinical trial using human umbilical cord-derived mesenchymal stem cells (UC-MSC) for multiple sclerosis from the Comit Nacional de Biotica de la Investigacin (CNEI) Institutional Review Board (IRB) in Panama.

According to the US National Multiple Sclerosis Society, in Multiple Sclerosis (MS), an abnormal immune-mediated T cell response attacks the myelin coating around nerve fibers in the central nervous system, as well as the nerve fibers themselves. This causes nerve impulses to slow or even halt, thus producing symptoms of MS that include fatigue; bladder and bowel problems; vision problems; and difficulty walking. The Cleveland Clinic reports that MS affects more than 350,000 people in the United States and 2.5 million worldwide.

Mesenchymal stem cells harvested from donated human umbilical cords after normal, healthy births possess anti-inflammatory and immune modulatory properties that may relieve MS symptoms. Because these cells are immune privileged, the recipients immune system does not reject them. These properties make UC-MSC interesting candidates for the treatment of multiple sclerosis and other autoimmune disorders.

Each patient will receive seven intravenous injections of UC-MSC over the course of 10 days. They will be assessed at 3 months and 12 months primarily for safety and secondarily for indications of efficacy.

The stem cell technology being utilized in this trial was developed by Neil Riordan, PhD, founder of Medistem Panama. The stem cells will be harvested and processed at Medistem Panamas 8000 sq. ft. ISO-9001 certified laboratory in the prestigious City of Knowledge. They will be administered at the Stem Cell Institute in Panama City, Panama.

From his research laboratory in Dallas, Texas, Dr. Riordan commented, Umbilical cord tissue provides an abundant, non-controversial supply of immune modulating mesenchymal stem cells. Preclinical and clinical research has demonstrated the anti-inflammatory and immune modulating effects of these cells. We look forward to the safety and efficacy data that will be generated by this clinical trial; the first in the western hemisphere testing the effects of umbilical cord mesenchymal stem cells on patients with multiple sclerosis.

The Principle Investigator is Jorge Paz-Rodriguez, MD. Dr. Paz-Rodriguez also serves as the Medical Director at the Stem Cell Institute.

For detailed information about this clinical trial visit http://www.clinicaltrials.gov . If you are a multiple sclerosis patient between the ages of 18 and 55, you may qualify for this trial. Please email trials (at) translationalbiosciences (dot) com for more information about how to apply.

About Translational Biosciences

View post:
Umbilical Cord Stem Cell Therapy Clinical Trial for Multiple Sclerosis Gets Green Light

Posted in Stem Cell Therapy | Comments Off on Umbilical Cord Stem Cell Therapy Clinical Trial for Multiple Sclerosis Gets Green Light

New York Podiatrist Dr. Jeffrey Adler to Be Interviewed April 5 on NewsTalkRadio 77 WABC About the Use of Stem Cell …

Posted: April 4, 2014 at 7:40 am

New York, New York (PRWEB) April 03, 2014

Dr. Jeffrey Adler, New York podiatrist and Owner/Medical Director of Adler Footcare New York, will be interviewed by radio personality Laura Smith and taking live calls on New York talk show 77 WABC about the use of stem cells to treat chronic foot pain.

Adler Footcare New York uses live birth stem cells to help treat patients with chronic foot problems such as: Plantar fasciitis, Osteoarthritis, Achilles tendonitis and torn soft tissue. The stem cell treatment is proving to be much more effective than traditional treatments like physical therapy or orthotic therapy.

Stem cells have the ability to replicate themselves or change into the cell type that is needed to repair damaged tissue. The therapy works by directly introducing live stem cells into the affected area causing pain. Its approved by the FDA and consistently reviewed by medical professionals to remove the potential of any communicable diseases.

Dr. Adler often travels to other states to share his knowledge with other doctors in his profession. His latest research on stem cell therapy has gained much interest among his peers in the medical industry.

When compared to traditional treatments, stem therapy is proving to be more successful and longer lasting, Dr. Adler said. We are seeing patients heal much quicker and return to their normal activities much sooner.

To learn more about stem cell replacement therapy or to schedule a consultation with a New York podiatrist at Adler Footcare, call (212) 704-4310 or visit http://www.mynycpodiatrist.com.

About Adler Footcare New York Dr. Jeffrey L. Adler, Medical/Surgical Director and owner of Adler Footcare New York has been practicing podiatric medicine since 1979 and has performed thousands of foot and ankle surgeries. Dr. Adler is board certified in Podiatric Surgery and Primary Podiatric Medicine by the American Board of Multiple Specialties in Podiatry. Dr. Adler is also a Professor of Minimally Invasive Foot Surgery for the Academy of Ambulatory Foot and Ankle Surgeons. As one of only several in the country who perform minimally invasive podiatric surgery, Dr. Adlers patients enjoy significantly reduced recovery times.

Originally posted here:
New York Podiatrist Dr. Jeffrey Adler to Be Interviewed April 5 on NewsTalkRadio 77 WABC About the Use of Stem Cell ...

Posted in Stem Cell Therapy | Comments Off on New York Podiatrist Dr. Jeffrey Adler to Be Interviewed April 5 on NewsTalkRadio 77 WABC About the Use of Stem Cell …

Page 2,147«..1020..2,1462,1472,1482,149..2,1602,170..»